You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Universal Attenuated Sporozoite Vaccine and Challenge System

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT Sanaria s Plasmodium falciparumPfsporozoiteSPZvaccines development program is receiving global supportTrials of PfSPZ Vaccineradiation attenuated PfSPZor PfSPZ CVacPfSPZ Chemoprophylaxis Vaccineadministered by direct venous inoculationDVIincludingadults to infants were initiated in DecemberTanzaniaU Sor will be initiated in earlyin MaliKenyainfantsGhanaEquatorial GuineaGermany andaddition ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Protease chain reactions for molecular analysis of cancer markers

    SBC: POTOMAC AFFINITY PROTEIN LLC            Topic: 102

    DESCRIPTION provided by applicant Our objective is to develop a Protease Chain Reaction technology ProCR that will enable ultra sensitive and highly quantitative detection of cancer markers The basic element of a protease chain reaction is a protease inhibitor complex The protease is inactive when bound to the inhibitor but once freed is capable of cleaving the inhibitor and releasing ad ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Software for improved accuracy and rapid tracking of kinematics from dynamic Xray

    SBC: C-MOTION, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant Orthopaedic disorders are a leading cause of disability in the U S with arthritis and or spine problems adversely affecting quality of life fo more than of adults While advances in diagnostic imaging have greatly improved our ability to detect structural changes in musculoskeletal tissues they typically reveal little about joint function There is evid ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Computerizing NIAAA's Best Practices for Youth Screening and Brief Intervention

    SBC: COG ANALYTICS, LLC            Topic: 400

    DESCRIPTION provided by applicant The early onset of alcohol misuse during adolescence is a widespread problem in the U S Studies have consistently documented both the short and long term adverse neurophysiological impacts and health risk behaviors associated with alcohol misuse during adolescence Given the magnitude of this problem and its myriad consequences preventing early initiation of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. A method for accurate and sensitive detection of HIV drug-resistant minority variants

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Effectiveness of VBP15, a dissociative steroidal analogue, on chronic inflammation in a mouse model of multiple sclerosis

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Glucocorticoids GCandapos s such as prednisolone are used frequently to induce remission and treat multiple sclerosis MS Despite effectiveness many GC mediated detrimental side effects including osteoporosis and muscle atrophy limit long term chronic treatment of MS patients These side effects are believed to be mediated by well described glucocorticoi ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Immuno-CometChip for Human Skin Basal Cell Genotoxicity Testing

    SBC: TREVIGEN, INC.            Topic: 113

    DESCRIPTION provided by applicant The objective of this Phase STTR research is to quantify genotoxicity in basal cell keratinocytes from organotypic cultures Epiderm in response to commonly used chemical agents The proposed product is a Comet Chip assay that measures DNA damage in basal cells derived from a reconstructed human epidermis Technical questions that will be addressed are Ca ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Bloodstream infection detection directly on whole blood

    SBC: SCANOGEN INC.            Topic: R

    DESCRIPTION provided by applicant Sepsis is a whole body inflammatory response to infection that affects approximately million people each year in the United States and kills up to percent of severely affected patients Rapid and appropriate antimicrobial administration is critical for the management of sepsis Each hour of treatment delay is associated with an decrease of survival in s ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Manufacture of aseptic purified cryopreserved Plasmodium vivax sporozoites PvSPZ Challenge for controlled human malaria infection CHMI

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION provided by applicant Plasmodium vivax Pv the second most important human malaria parasite causes more than million cases annually including severe fatal disease Prevention and control are challenged by emerging drug resistance and relapses from dormant liver stage parasites called hypnozoites The only therapy against relapse primaquine causes life threatening acute hemo ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government